Hints and tips:
Related Special Reports
...Since taking the helm in 2012, Soriot has turned AstraZeneca into the second-largest company on the FTSE 100 index behind Shell....
...Emma Walmsley, chief executive of AstraZeneca’s British rival GSK, earned £12.7mn in 2023....
...AstraZeneca has a market capitalisation of £171bn....
...Late last year, AstraZeneca agreed to buy its first vaccine company, Icosovax, in a deal worth up to $1.1bn....
...Companies including the London Stock Exchange Group and AstraZeneca are proposing pay increases for their bosses against a backdrop of concerns about the UK’s international competitiveness....
...AstraZeneca signed its first for-profit deals in late 2021, as the company said the pandemic had moved into an “endemic phase”....
...The writer is chair of AstraZeneca The AGM season is in full swing, and with it comes the usual set of controversies around remuneration....
...Soriot said on Thursday that AstraZeneca’s deal activity would continue but “at a slower pace”....
...AstraZeneca is starting its next 10-year cycle from a very different place....
...“Some of our loyal shareholders do expect cash dividends as an important part of total returns,” said AstraZeneca chair Michel Demaré at the AGM....
...Shares in AstraZeneca dipped 1.1 per cent in morning trading....
...These data reinforce that message,” said Susan Galbraith, executive vice-president of oncology R&D at AstraZeneca....
...AstraZeneca’s jab developed with Oxford university was widely used across the world, but sales fell more than 99 per cent to just $12mn in 2023....
...Muir had worked at AstraZeneca, which has more than 8,700 employees in the UK, since 1998....
...In August, AstraZeneca signed a deal with China’s CanSino Biologics for the production of its potential mRNA vaccines....
...The deal is expected to close in the first quarter of next year, AstraZeneca said....
...AstraZeneca updated the label to warn recipients of the concern on April 7 and April 15....
...The agreement is part of AstraZeneca’s ambitious plans to replace traditional chemotherapy with a new generation of targeted drugs....
...GSK, AstraZeneca, Novo Nordisk and Novartis were among 10 companies to receive letters from the FTC on Tuesday informing them that the agency had disputed a number of patents with the Food and Drug Administration...
...Galbraith did not comment on whether AstraZeneca had bid to partner on the next drugs in the pipeline....
...Shares in AstraZeneca climbed 3 per cent on Thursday, having lost 9.2 per cent in the year to date period....
...AstraZeneca shares are down about 4.5 per cent in the year so far....
...crunchy acronym was coined by Goldman Sachs for pharma companies GSK and Roche, Dutch chip company ASML, Switzerland’s Nestlé and Novartis, Danish drugmaker Novo Nordisk, France’s L’Oréal and LVMH, the UK’s AstraZeneca...
...AstraZeneca chair sees past vaccine headwinds Michel Demaré, non-executive chair of the AstraZeneca board, appears bullish about the company’s prospects....
...The medical devices company is the latest FTSE company to withstand a shareholder revolt on large hikes to chief executive pay, after AstraZeneca, the London Stock Exchange Group and Ocado all faced down...
International Edition